A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY OF FEVIPIPRANT ONCE DAILY PLUS STANDARD-OF-CARE (SOC) FOR ASSESSMENT OF THE EFFICACY IN REDUCTION OF NASAL POLYPS SIZE IN PATIENTS WITH NASAL POLYPOSIS AND CONCOMITANT ASTHMA

Registry ID
CQAW039A2322
Source registry
HEALTH_CANADA
Status
Ongoing
Study type
INTERVENTIONAL
Sponsor
NOVARTIS PHARMACEUTICALS CANADA INC
Start date
2019-04-17
Last update
2018-12-05

Conditions

Related clinical trials

View on source registry